$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000154422718000009 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	-$200.0K	$55.00K	$90.00K
YoY Change	-322.22%	-1.79%	-25.0%
Cost Of Revenue		$44.00K	$220.0K
YoY Change		51.72%	-84.62%
Gross Profit		$11.00K	-$130.0K
YoY Change		-59.26%	-90.08%
Gross Profit Margin		20.0%	-144.44%
Selling, General & Admin	$1.400M	$4.176M	$4.810M
YoY Change	-70.89%	-17.41%	-56.07%
% of Gross Profit		37963.64%
Research & Development	$7.730M	$1.680M	$3.560M
YoY Change	117.13%	-58.17%	-24.42%
% of Gross Profit		15272.73%
Depreciation & Amortization	-$600.0K	$100.0K	$340.0K
YoY Change	-276.47%	-75.0%	-42.37%
% of Gross Profit		909.09%
Operating Expenses	$5.290M	$5.953M	$8.370M
YoY Change	-36.8%	-37.09%	-46.55%
Operating Profit		-$5.898M	-$8.500M
YoY Change		-37.3%	-49.91%
Interest Expense	-$980.0K	$230.0K	$190.0K
YoY Change	-615.79%	360.0%	-190.48%
% of Operating Profit
Other Income/Expense, Net	$50.00K	-$7.000K	$0.00
YoY Change		133.33%	-100.0%
Pretax Income	-$6.430M	-$5.679M	-$8.490M
YoY Change	-24.26%	-39.3%	-62.53%
Income Tax		$0.00	$30.00K
% Of Pretax Income
Net Earnings	-$6.440M	-$5.679M	-$8.530M
YoY Change	-24.5%	-39.37%	-62.32%
Net Earnings / Revenue		-10325.45%	-9477.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$133.10	-$35.50	-$53.31
COMMON SHARES
Basic Shares Outstanding	35.83M shares	35.79M shares	35.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.67M	$46.40M	$67.20M
YoY Change	15.58%	-38.71%	-41.26%
Cash & Equivalents	$73.29M	$31.92M	$15.70M
Short-Term Investments	$4.385M	$14.40M	$51.50M
Other Short-Term Assets	$3.400M	$2.600M	$1.600M
YoY Change	112.5%	36.84%	-23.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$83.42M	$48.99M	$68.78M
YoY Change	21.29%	-36.88%	-40.93%
LONG-TERM ASSETS
Property, Plant & Equipment		$108.0K	$3.113M
YoY Change		-97.0%	-44.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$140.0K	$146.0K
YoY Change			124.62%
Other Assets	$213.0K	$0.00	$24.00K
YoY Change	787.5%	-100.0%	4.35%
Total Long-Term Assets	$652.0K	$248.0K	$4.072M
YoY Change	-83.99%	-94.39%	-33.23%
TOTAL ASSETS
Total Short-Term Assets	$83.42M	$48.99M	$68.78M
Total Long-Term Assets	$652.0K	$248.0K	$4.072M
Total Assets	$84.07M	$49.23M	$72.85M
YoY Change	15.4%	-39.98%	-40.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.998M	$604.0K	$2.242M
YoY Change	-10.88%	-77.55%	2.7%
Accrued Expenses	$7.630M	$3.277M	$5.562M
YoY Change	37.18%	-47.25%	-49.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$189.0K
YoY Change
Total Short-Term Liabilities	$9.817M	$3.881M	$7.804M
YoY Change	25.79%	-56.41%	-40.92%
LONG-TERM LIABILITIES
Long-Term Debt	$383.0K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$752.0K	$442.0K	$751.0K
YoY Change	0.13%	-47.0%	-32.71%
Total Long-Term Liabilities	$1.135M	$442.0K	$751.0K
YoY Change	51.13%	-47.0%	-32.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.817M	$3.881M	$7.804M
Total Long-Term Liabilities	$1.135M	$442.0K	$751.0K
Total Liabilities	$10.95M	$4.323M	$8.555M
YoY Change	28.02%	-55.6%	-40.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.1M	-$322.2M	-$301.5M
YoY Change	-45.57%	9.99%	20.51%
Common Stock	$13.00K	$36.00K	$36.00K
YoY Change	-63.89%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$70.95M	$44.91M	$64.30M
YoY Change
Total Liabilities & Shareholders Equity	$84.07M	$49.23M	$72.85M
YoY Change	15.4%	-39.98%	-40.55%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$6.440M	-$5.679M	-$8.530M
YoY Change	-24.5%	-39.37%	-62.32%
Depreciation, Depletion And Amortization	-$600.0K	$100.0K	$340.0K
YoY Change	-276.47%	-75.0%	-42.37%
Cash From Operating Activities	-$2.160M	-$7.730M	-$7.970M
YoY Change	-72.9%	-24.95%	-46.72%
INVESTING ACTIVITIES
Capital Expenditures	$40.00K	-$150.0K	$50.00K
YoY Change	-20.0%	-1600.0%	-96.75%
Acquisitions
YoY Change
Other Investing Activities	-$35.74M	$14.90M	-$1.060M
YoY Change	3271.7%	26.49%	-110.63%
Cash From Investing Activities	-$35.78M	$15.05M	-$1.100M
YoY Change	3152.73%	27.98%	-113.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$18.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	77.74M	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.160M	-7.730M	-7.970M
Cash From Investing Activities	-35.78M	15.05M	-1.100M
Cash From Financing Activities	77.74M	0.000	0.000
Net Change In Cash	39.80M	7.320M	-9.070M
YoY Change	-538.81%	401.37%	38.47%
FREE CASH FLOW
Cash From Operating Activities	-$2.160M	-$7.730M	-$7.970M
Capital Expenditures	$40.00K	-$150.0K	$50.00K
Free Cash Flow	-$2.200M	-$7.580M	-$8.020M
YoY Change	-72.57%	-26.48%	-51.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	4	security
CY2018Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4	security
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35826429	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1300000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	438000	USD
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	633000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1311000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
	dei	Entity Small Business EntitySmallBusiness	true
CY2017Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1542000	USD
CY2018Q3	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	422000	USD
CY2017Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	160000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2018Q3	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	142000	USD
CY2017Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	519000	USD
CY2018Q3	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	0	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2242000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	604000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5562000	USD
CY2018Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3277000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	300000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3700000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1670000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365769000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	367110000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	101000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2215000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1447000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-176000	USD
CY2017Q4	us-gaap	Assets Assets	72853000	USD
CY2018Q3	us-gaap	Assets Assets	49234000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	68781000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	48986000	USD
CY2018Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	100000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2018Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	300000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	200000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	67230000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	46353000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	146000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67203000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46350000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	353000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24775000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15703000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31917000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	46400000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35725230	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35826429	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35725230	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35826429	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9340000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42409000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5674000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5562000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3277000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20728000	USD
CY2018Q3	us-gaap	Equity Method Investments EquityMethodInvestments	140000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	29000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	572000	USD
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	44000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	210000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	22900000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	8600000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	10	security
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	334000	USD
CY2018Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	66000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	250000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	2203000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9356000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42414000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5679000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20752000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-140000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1015000	USD
CY2018Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	517000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1638000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5440000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2594000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-24000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-635000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	473000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	193000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	560000	USD
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	228000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	643000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	82000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8555000	USD
	us-gaap	Operating Expenses OperatingExpenses	42126000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21492000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9367000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42447000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-5679000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20752000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9462000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18774000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	37706000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37579000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	4323000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72853000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49234000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7804000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3881000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-18805000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	16214000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	5953000	USD
	us-gaap	Operating Expenses OperatingExpenses	21587000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9406000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-41922000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5898000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21384000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	792000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	913000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	751000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	442000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	1842000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	550000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48403000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	33491000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1578000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1847000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	67839000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	70759000	USD
CY2017Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	300000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	200000	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	200000	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	200000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6813000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1778000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4016000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14777000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1680000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6695000	USD
CY2017Q3	us-gaap	Restricted Cash RestrictedCash	789000	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	789000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	44369000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	25564000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16492000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	32706000	USD
CY2017Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	789000	USD
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2018Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	789000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	789000	USD
CY2018Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2018Q3	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	12900000	USD
CY2017Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.50
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	400000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	361000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3842000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3800000	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	53000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3637000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	403000	USD
CY2018Q3	us-gaap	Restructuring Reserve RestructuringReserve	47000	USD
CY2018Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	100000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301480000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-322232000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	204000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	203000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5056000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22935000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4176000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11045000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6377000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1259000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.65
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.70
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	192500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4207856	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	72000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1251877	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.51
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.95
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.96
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	51500000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	14433000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	64298000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	44911000	USD
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	2200000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35687000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35664000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35790000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35759000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates and summary of significant accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with US GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in our 2017 Annual Report on Form 10-K.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-18-000009-index-headers.html	Edgar Link	pending
0001544227-18-000009-index.html	Edgar Link	pending
0001544227-18-000009.txt	Edgar Link	pending
0001544227-18-000009-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20180930.xml	Edgar Link	completed
ovas-20180930.xsd	Edgar Link	pending
ovas-20180930x10q.htm	Edgar Link	pending
ovas-20180930xex22.htm	Edgar Link	pending
ovas-20180930xex311.htm	Edgar Link	pending
ovas-20180930xex312.htm	Edgar Link	pending
ovas-20180930xex321.htm	Edgar Link	pending
ovas-20180930xex322.htm	Edgar Link	pending
ovas-20180930_cal.xml	Edgar Link	unprocessable
ovas-20180930_def.xml	Edgar Link	unprocessable
ovas-20180930_lab.xml	Edgar Link	unprocessable
ovas-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2018 Q4 Form 10-Q Financial Statement

#000154422718000009 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2018 Q4 Form 10-Q Financial Statement

#000154422718000009 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst